{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T22:41:01Z","timestamp":1720564861745},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","medical-hypotheses.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.mehy.2017.03.022","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T23:46:42Z","timestamp":1489448802000},"page":"78-81","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Interleukin-1beta may act on hepatocytes to boost plasma homocysteine \u2013 The increased cardiovascular risk associated with elevated homocysteine may be mediated by this cytokine"],"prefix":"10.1016","volume":"102","author":[{"given":"Mark F.","family":"McCarty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"O'Keefe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"DiNicolantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.mehy.2017.03.022_b0005","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.296.22.2720","article-title":"Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials","volume":"296","author":"Bazzano","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2017.03.022_b0010","first-page":"CD006612","article-title":"Homocysteine lowering interventions for preventing cardiovascular events","volume":"4","author":"Marti-Carvajal","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.mehy.2017.03.022_b0015","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.ejim.2012.07.004","article-title":"Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials","volume":"23","author":"Yang","year":"2012","journal-title":"Eur J Intern Med"},{"issue":"6","key":"10.1016\/j.mehy.2017.03.022_b0020","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1742-1241.2012.02929.x","article-title":"Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis","volume":"66","author":"Huo","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"13","key":"10.1016\/j.mehy.2017.03.022_b0025","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jama.2015.2274","article-title":"Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial","volume":"313","author":"Huo","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.mehy.2017.03.022_b0030","doi-asserted-by":"publisher","DOI":"10.1177\/1747493016662038","article-title":"Homocysteine lowering for stroke prevention: unravelling the complexity of the evidence","author":"Spence","year":"2016","journal-title":"Int J Stroke"},{"issue":"4","key":"10.1016\/j.mehy.2017.03.022_b0035","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/ije\/dyl041","article-title":"Insight into the nature of the CRP-coronary event association using Mendelian randomization","volume":"35","author":"Casas","year":"2006","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.mehy.2017.03.022_b0040","doi-asserted-by":"publisher","first-page":"d548","DOI":"10.1136\/bmj.d548","article-title":"Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data","volume":"342","author":"Wensley","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.mehy.2017.03.022_b0045","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0050","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ijcard.2011.12.098","article-title":"Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach","volume":"157","author":"Niu","year":"2012","journal-title":"Int J Cardiol"},{"issue":"9822","key":"10.1016\/j.mehy.2017.03.022_b0055","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0060","first-page":"394","article-title":"Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion","volume":"121","author":"Bevilacqua","year":"1985","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0065","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1189\/jlb.72.3.503","article-title":"Interleukin-10 inhibits proinflammatory activation of endothelium in response to Borrelia burgdorferi or lipopolysaccharide but not interleukin-1beta or tumor necrosis factor alpha","volume":"72","author":"Lisinski","year":"2002","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.mehy.2017.03.022_b0070","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12933-014-0158-z","article-title":"The interleukin-1 receptor antagonist anakinra improves endothelial dysfunction in streptozotocin-induced diabetic rats","volume":"13","author":"Vallejo","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0075","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/0014-4827(89)90104-3","article-title":"Interleukin-1 promotes proliferation of vascular smooth muscle cells in coordination with PDGF or a monocyte derived growth factor","volume":"181","author":"Bonin","year":"1989","journal-title":"Exp Cell Res"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0080","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbrc.2013.05.002","article-title":"Arginase inhibition reduces interleukin-1beta-stimulated vascular smooth muscle cell proliferation by increasing nitric oxide synthase-dependent nitric oxide production","volume":"435","author":"Yoon","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.mehy.2017.03.022_b0085","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.vph.2015.04.013","article-title":"IL-1beta enhances vascular smooth muscle cell proliferation and migration via P2Y2 receptor-mediated RAGE expression and HMGB1 release","volume":"72","author":"Eun","year":"2015","journal-title":"Vascul Pharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0090","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1172\/JCI118476","article-title":"Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor","volume":"97","author":"Shimokawa","year":"1996","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.mehy.2017.03.022_b0095","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0100","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbrc.2011.01.008","article-title":"Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1alpha","volume":"405","author":"Kamari","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0105","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.atherosclerosis.2011.02.026","article-title":"Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice","volume":"216","author":"Bhaskar","year":"2011","journal-title":"Atherosclerosis"},{"issue":"1\u20132","key":"10.1016\/j.mehy.2017.03.022_b0110","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1023\/A:1024701715131","article-title":"Inhibition of interleukin-1beta convertase is associated with decrease of neointimal hyperplasia after coronary artery stenting in pigs","volume":"249","author":"Gyongyosi","year":"2003","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"10.1016\/j.mehy.2017.03.022_b0115","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00011-013-0667-3","article-title":"OxLDL-induced IL-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation","volume":"63","author":"Liu","year":"2014","journal-title":"Inflamm Res"},{"issue":"4","key":"10.1016\/j.mehy.2017.03.022_b0120","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"issue":"21","key":"10.1016\/j.mehy.2017.03.022_b0125","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mehy.2017.03.022_b0130","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8614.1","article-title":"Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation","volume":"5","author":"Prochnicki","year":"2016","journal-title":"F1000Res"},{"issue":"5","key":"10.1016\/j.mehy.2017.03.022_b0135","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/MCA.0000000000000255","article-title":"NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins","volume":"26","author":"Altaf","year":"2015","journal-title":"Coron Artery Dis"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0140","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1042\/CS20130043","article-title":"NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin","volume":"126","author":"Satoh","year":"2014","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.mehy.2017.03.022_b0145","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10557-013-6498-1","article-title":"Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model","volume":"28","author":"Luo","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0150","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1189\/jlb.0812409","article-title":"HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2X7 activation","volume":"93","author":"Liao","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"11","key":"10.1016\/j.mehy.2017.03.022_b0155","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.2337\/db13-1398","article-title":"Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance","volume":"63","author":"Henriksbo","year":"2014","journal-title":"Diabetes"},{"issue":"13","key":"10.1016\/j.mehy.2017.03.022_b0160","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1089\/ars.2012.4666","article-title":"NADPH oxidase-mediated triggering of inflammasome activation in mouse podocytes and glomeruli during hyperhomocysteinemia","volume":"18","author":"Abais","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.mehy.2017.03.022_b0165","doi-asserted-by":"publisher","first-page":"504761","DOI":"10.1155\/2015\/504761","article-title":"NADPH oxidase-induced NALP3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia","volume":"2015","author":"Gao","year":"2015","journal-title":"J Diabetes Res"},{"issue":"5","key":"10.1016\/j.mehy.2017.03.022_b0170","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1160\/TH14-07-0628","article-title":"Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome","volume":"113","author":"Muller-Calleja","year":"2015","journal-title":"Thromb Haemost"},{"issue":"17","key":"10.1016\/j.mehy.2017.03.022_b0175","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/smll.201402859","article-title":"NADPH oxidase-dependent NLRP3 inflammasome activation and its important role in lung fibrosis by multiwalled carbon nanotubes","volume":"11","author":"Sun","year":"2015","journal-title":"Small"},{"issue":"1","key":"10.1016\/j.mehy.2017.03.022_b0180","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/01.ATV.20.1.61","article-title":"Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation","volume":"20","author":"Wagner","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.mehy.2017.03.022_b0185","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1055\/s-0031-1283148","article-title":"Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1","volume":"43","author":"Ishibashi","year":"2011","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0190","doi-asserted-by":"publisher","first-page":"H1264","DOI":"10.1152\/ajpheart.00804.2005","article-title":"Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production","volume":"290","author":"Erdos","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1\u20133","key":"10.1016\/j.mehy.2017.03.022_b0195","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejphar.2013.04.025","article-title":"Pleiotropic antioxidant potential of rosuvastatin in preventing cardiovascular disorders","volume":"711","author":"Mahalwar","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"13","key":"10.1016\/j.mehy.2017.03.022_b0200","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2174\/1389450115666141027110156","article-title":"Rac-1 as a new therapeutic target in cerebro- and cardio-vascular diseases","volume":"15","author":"Carrizzo","year":"2014","journal-title":"Curr Drug Targets"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0205","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1755-5922.2011.00310.x","article-title":"Opportunity nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease","volume":"31","author":"Streeter","year":"2013","journal-title":"Cardiovasc Ther"},{"issue":"5\u20136","key":"10.1016\/j.mehy.2017.03.022_b0210","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.vph.2012.02.012","article-title":"Targeting NADPH oxidases in vascular pharmacology","volume":"56","author":"Schramm","year":"2012","journal-title":"Vascul Pharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0215","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S0163-7258(96)00197-0","article-title":"S-adenosylmethionine synthesis: molecular mechanisms and clinical implications","volume":"73","author":"Mato","year":"1997","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0220","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0168-8278(00)00022-2","article-title":"Short-chain ceramide regulates hepatic methionine adenosyltransferase expression","volume":"34","author":"Frago","year":"2001","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.mehy.2017.03.022_b0225","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1172\/JCI200419852","article-title":"Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis","volume":"113","author":"Mari","year":"2004","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.mehy.2017.03.022_b0230","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1096\/fj.03-0875fje","article-title":"Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-beta-induced JNK activation","volume":"18","author":"Karakashian","year":"2004","journal-title":"FASEB J"},{"issue":"11","key":"10.1016\/j.mehy.2017.03.022_b0235","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1194\/jlr.M500337-JLR200","article-title":"Ceramide- and ERK-dependent pathway for the activation of CCAAT\/enhancer binding protein by interleukin-1beta in hepatocytes","volume":"46","author":"Giltiay","year":"2005","journal-title":"J Lipid Res"},{"issue":"11","key":"10.1016\/j.mehy.2017.03.022_b0240","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1194\/jlr.M700227-JLR200","article-title":"Regulation of neutral sphingomyelinase-2 by GSH: a new insight to the role of oxidative stress in aging-associated inflammation","volume":"48","author":"Rutkute","year":"2007","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.mehy.2017.03.022_b0245","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.abb.2004.08.037","article-title":"Redox regulation and reaction mechanism of human cystathionine-beta-synthase: a PLP-dependent hemesensor protein","volume":"433","author":"Banerjee","year":"2005","journal-title":"Arch Biochem Biophys"},{"issue":"8","key":"10.1016\/j.mehy.2017.03.022_b0250","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1053\/meta.2002.34017","article-title":"Elevated plasma total homocysteine in severe methionine adenosyltransferase I\/III deficiency","volume":"51","author":"Stabler","year":"2002","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.mehy.2017.03.022_b0255","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s10545-005-4497-5","article-title":"Methionine adenosyltransferase (MAT) I\/III deficiency with concurrent hyperhomocysteinaemia: two novel cases","volume":"28","author":"Linnebank","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.mehy.2017.03.022_b0260","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/8904_2011_124","article-title":"Methionine adenosyltransferase I\/III deficiency in Portugal: high frequency of a dominantly inherited form in a small area of douro high lands","volume":"6","author":"Martins","year":"2012","journal-title":"JIMD Rep"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0265","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.numecd.2009.08.003","article-title":"Associations of plasma homocysteine level with brachial-ankle pulse wave velocity, LDL atherogenicity, and inflammation profile in healthy men","volume":"21","author":"Yun","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0270","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2174\/1567205011310020007","article-title":"Pro-inflammatory cytokines IL-1beta and TNF-alpha are not associated with plasma homocysteine concentration in Alzheimer's disease","volume":"10","author":"Veryard","year":"2013","journal-title":"Curr Alzheimer Res"},{"issue":"20","key":"10.1016\/j.mehy.2017.03.022_b0275","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1053\/euhj.2002.3172","article-title":"Smoking and plasma homocysteine","volume":"23","author":"O'Callaghan","year":"2002","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.mehy.2017.03.022_b0280","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1515\/CCLM.2004.072","article-title":"The influence of smoking on plasma homocysteine and cysteine levels in passive and active smokers","volume":"42","author":"Sobczak","year":"2004","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0285","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/cvr\/cvr032","article-title":"Cytokines present in smokers' serum interact with smoke components to enhance endothelial dysfunction","volume":"90","author":"Barbieri","year":"2011","journal-title":"Cardiovasc Res"},{"issue":"10","key":"10.1016\/j.mehy.2017.03.022_b0290","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1183\/09031936.96.09101989","article-title":"Dose-dependent cigarette smoking-related inflammatory responses in healthy adults","volume":"9","author":"Kuschner","year":"1996","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.mehy.2017.03.022_b0295","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/j.1600-0765.2012.01468.x","article-title":"Influence of smoking on interleukin-1beta level, oxidant status and antioxidant status in gingival crevicular fluid from chronic periodontitis patients before and after periodontal treatment","volume":"47","author":"Toker","year":"2012","journal-title":"J Periodontal Res"},{"issue":"4","key":"10.1016\/j.mehy.2017.03.022_b0300","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1002\/art.1780400418","article-title":"Abnormal homocysteine metabolism in rheumatoid arthritis","volume":"40","author":"Roubenoff","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.mehy.2017.03.022_b0305","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0009-9120(98)00093-9","article-title":"Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women","volume":"32","author":"Hernanz","year":"1999","journal-title":"Clin Biochem"},{"issue":"1","key":"10.1016\/j.mehy.2017.03.022_b0310","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/205873929901200103","article-title":"Combination of methotrexate and prednizone decreases circulating concentrations of interleukin 1 beta and Interleukin 6 in patients with rheumatoid arthritis. Poor correlation of cytokine suppression with clinical improvement","volume":"12","author":"Nowak","year":"1999","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"11","key":"10.1016\/j.mehy.2017.03.022_b0315","first-page":"1343","article-title":"Concentration of interleukin-1 beta in serum and synovial fluid in patients with rheumatoid arthritis and those with osteoarthritis","volume":"63","author":"Mannami","year":"1989","journal-title":"Nihon Seikeigeka Gakkai Zasshi"},{"issue":"5","key":"10.1016\/j.mehy.2017.03.022_b0320","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF02274836","article-title":"Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis","volume":"10","author":"Rooney","year":"1990","journal-title":"Rheumatol Int"},{"issue":"16","key":"10.1016\/j.mehy.2017.03.022_b0325","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1161\/hc4101.097518","article-title":"Risk factors for cardiovascular disease in systemic lupus erythematosus","volume":"104","author":"Svenungsson","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.mehy.2017.03.022_b0330","first-page":"594","article-title":"Increased concentration of plasma homocysteine in children with systemic lupus erythematosus","volume":"24","author":"Do","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0335","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.pharep.2015.08.019","article-title":"Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases","volume":"68","author":"Pytel","year":"2016","journal-title":"Pharmacol Rep"},{"issue":"2","key":"10.1016\/j.mehy.2017.03.022_b0340","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/0003319714522107","article-title":"Beneficial effects of rosuvastatin treatment in patients with metabolic syndrome","volume":"66","author":"Bostan","year":"2015","journal-title":"Angiology"},{"issue":"3","key":"10.1016\/j.mehy.2017.03.022_b0345","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1742-7843.2008.00293.x","article-title":"Effect of rosuvastatin on methionine-induced hyperhomocysteinaemia and haematological changes in rats","volume":"103","author":"Nigam","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.mehy.2017.03.022_b0350","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1002\/acr.20440","article-title":"Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Mok","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.mehy.2017.03.022_b0355","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1177\/000331970505600510","article-title":"Starting with rosuvastatin in primary hyperlipidemia\u2013Is there more than lipid lowering?","volume":"56","author":"Milionis","year":"2005","journal-title":"Angiology"},{"issue":"23","key":"10.1016\/j.mehy.2017.03.022_b0360","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716308994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987716308994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T12:24:53Z","timestamp":1692707093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987716308994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":72,"alternative-id":["S0306987716308994"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2017.03.022","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-1beta may act on hepatocytes to boost plasma homocysteine \u2013 The increased cardiovascular risk associated with elevated homocysteine may be mediated by this cytokine","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2017.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}